-
Je něco špatně v tomto záznamu ?
First independent validation of the proton-boron capture therapy concept
A. Jelínek Michaelidesová, P. Kundrát, O. Zahradníček, I. Danilová, K. Pachnerová Brabcová, J. Vachelová, J. Vilimovský, M. David, V. Vondráček, M. Davídková
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
21-06451S
Czech Science Foundation
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
- MeSH
- bor chemie MeSH
- glioblastom radioterapie farmakoterapie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- nádory prostaty radioterapie farmakoterapie MeSH
- protonová terapie * metody MeSH
- protony MeSH
- terapie metodou neutronového záchytu (bor-10) * metody MeSH
- viabilita buněk účinky léků účinky záření MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Boron has been suggested to enhance the biological effectiveness of proton beams in the Bragg peak region via the p + 11B → 3α nuclear capture reaction. However, a number of groups have observed no such enhancement in vitro or questioned its proposed mechanism recently. To help elucidate this phenomenon, we irradiated DU145 prostate cancer or U-87 MG glioblastoma cells by clinical 190 MeV proton beams in plateau or Bragg peak regions with or without 10B or 11B isotopes added as sodium mercaptododecaborate (BSH). The results demonstrate that 11B but not 10B or other components of the BSH molecule enhance cell killing by proton beams. The enhancement occurs selectively in the Bragg peak region, is present for boron concentrations as low as 40 ppm, and is not due to secondary neutrons. The enhancement is likely initiated by proton-boron capture reactions producing three alpha particles, which are rare events occurring in a few cells only, and their effects are amplified by intercellular communication to a population-level response. The observed up to 2-3-fold reductions in survival levels upon the presence of boron for the studied prostate cancer or glioblastoma cells suggest promising clinical applications for these tumour types.
Nuclear Physics Institute of the Czech Academy of Sciences Husinec Řež 130 250 68 Řež Czech Republic
Proton Therapy Center Czech Prague Budínova 2437 1a 180 00 Prague Czech Republic
Thomayer University Hospital Vídeňská 800 140 59 Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019301
- 003
- CZ-PrNML
- 005
- 20241024111517.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-024-69370-y $2 doi
- 035 __
- $a (PubMed)39164312
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Jelínek Michaelidesová, Anna $u Nuclear Physics Institute of the Czech Academy of Sciences, Husinec - Řež 130, 250 68, Řež, Czech Republic $u Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 78/7, 115 19, Prague, Czech Republic
- 245 10
- $a First independent validation of the proton-boron capture therapy concept / $c A. Jelínek Michaelidesová, P. Kundrát, O. Zahradníček, I. Danilová, K. Pachnerová Brabcová, J. Vachelová, J. Vilimovský, M. David, V. Vondráček, M. Davídková
- 520 9_
- $a Boron has been suggested to enhance the biological effectiveness of proton beams in the Bragg peak region via the p + 11B → 3α nuclear capture reaction. However, a number of groups have observed no such enhancement in vitro or questioned its proposed mechanism recently. To help elucidate this phenomenon, we irradiated DU145 prostate cancer or U-87 MG glioblastoma cells by clinical 190 MeV proton beams in plateau or Bragg peak regions with or without 10B or 11B isotopes added as sodium mercaptododecaborate (BSH). The results demonstrate that 11B but not 10B or other components of the BSH molecule enhance cell killing by proton beams. The enhancement occurs selectively in the Bragg peak region, is present for boron concentrations as low as 40 ppm, and is not due to secondary neutrons. The enhancement is likely initiated by proton-boron capture reactions producing three alpha particles, which are rare events occurring in a few cells only, and their effects are amplified by intercellular communication to a population-level response. The observed up to 2-3-fold reductions in survival levels upon the presence of boron for the studied prostate cancer or glioblastoma cells suggest promising clinical applications for these tumour types.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a terapie metodou neutronového záchytu (bor-10) $x metody $7 D016754
- 650 12
- $a protonová terapie $x metody $7 D061766
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a nádory prostaty $x radioterapie $x farmakoterapie $7 D011471
- 650 _2
- $a glioblastom $x radioterapie $x farmakoterapie $7 D005909
- 650 _2
- $a bor $x chemie $7 D001895
- 650 _2
- $a viabilita buněk $x účinky léků $x účinky záření $7 D002470
- 650 _2
- $a protony $7 D011522
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kundrát, Pavel $u Nuclear Physics Institute of the Czech Academy of Sciences, Husinec - Řež 130, 250 68, Řež, Czech Republic
- 700 1_
- $a Zahradníček, Oldřich $u Nuclear Physics Institute of the Czech Academy of Sciences, Husinec - Řež 130, 250 68, Řež, Czech Republic
- 700 1_
- $a Danilová, Irina $u Nuclear Physics Institute of the Czech Academy of Sciences, Husinec - Řež 130, 250 68, Řež, Czech Republic $u Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 78/7, 115 19, Prague, Czech Republic
- 700 1_
- $a Pachnerová Brabcová, Kateřina $u Nuclear Physics Institute of the Czech Academy of Sciences, Husinec - Řež 130, 250 68, Řež, Czech Republic
- 700 1_
- $a Vachelová, Jana $u Nuclear Physics Institute of the Czech Academy of Sciences, Husinec - Řež 130, 250 68, Řež, Czech Republic
- 700 1_
- $a Vilimovský, Jan $u Proton Therapy Center Czech, Prague, Budínova 2437/1a, 180 00, Prague, Czech Republic
- 700 1_
- $a David, Miroslav $u Thomayer University Hospital, Vídeňská 800, 140 59, Prague, Czech Republic
- 700 1_
- $a Vondráček, Vladimír $u Proton Therapy Center Czech, Prague, Budínova 2437/1a, 180 00, Prague, Czech Republic $u Thomayer University Hospital, Vídeňská 800, 140 59, Prague, Czech Republic
- 700 1_
- $a Davídková, Marie $u Nuclear Physics Institute of the Czech Academy of Sciences, Husinec - Řež 130, 250 68, Řež, Czech Republic. davidkova@ujf.cas.cz
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 14, č. 1 (2024), s. 19264
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39164312 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111511 $b ABA008
- 999 __
- $a ok $b bmc $g 2201874 $s 1231274
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 14 $c 1 $d 19264 $e 20240820 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a 21-06451S $p Czech Science Foundation
- LZP __
- $a Pubmed-20241015